iRhythm Beats Q2 Revenue, Raises Guidance, and Acquires Vital Connect for $287.5M
IRTC sits 27% above its 52-week low of $100.846 on elevated volume (2.1× avg).
Summary
iRhythm delivered a strong Q2 with revenue of $224.2M, beating the $219.3M consensus, and swung to an adjusted net income of $19.3M from a loss a year ago. The company raised its full-year 2026 revenue guidance to $880M-$890M and expects adjusted EBITDA margins of 13%-14%, signaling confidence in sustained volume growth and margin expansion. In a strategic move, iRhythm announced the acquisition of Vital Connect for $287.5M to broaden its cardiac monitoring platform. This follows a cybersecurity incident disclosed in June and a $45M securities litigation settlement in May, but the operational momentum appears intact. The stock, trading at 190x forward earnings, reflects high growth expectations that these results reinforce.
Updates
· SEC 8-K — The merger agreement provides $237.5M cash and $50M in stock, with a $30M indemnity escrow and a $9M reverse termination fee. iRhythm will also provide up to $30M in interim funding, with an initial $10M.
At the time of this announcement, IRTC was trading at $128.12 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.2B. The 52-week trading range was $100.85 to $212.00. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Reuters.